Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Bladder Cancer, March 2026 Free Subscription Abstracts Retrieve all available abstracts of the following 81 articles: HTML format

Single Articles

1. WALLERSON J, Rostampour S, Teng S, Kidane D, et al
   Dysregulated Peroxiredoxins in Bladder Cancer Are Associated With an Altered Tumour Immune Microenvironment.
   J Cell Mol Med. 2026;30:e71064.
   PubMed    
   Abstract available
   
   

2. MELLEMA JJ, Stockem CF, Herberts C, Cheung SK, et al
   Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
   Nat Med. 2026 Feb 27. doi: 10.1038/s41591-026-04271.
   PubMed    
   Abstract available
   
   

3. SHENG Y, Fan L, Zhu S, Wang Y, et al
   Combined and individual effects of neoadjuvant chemotherapy and lymph node dissection on survival in non-muscle-invasive bladder cancer undergoing radical cystectomy.
   Urol Oncol. 2026;44:111039.
   PubMed    
   Abstract available
   
   

4. DENG Z, Yan Z, Chen Z
   Post-translational modifications: Principal regulators of bladder cancer.
   Mol Biol Rep. 2026;53:446.
   PubMed    
   
   
   

5. LI Y, Ma Y, Lai J, Wan Q, et al
   Exploring the potential mechanisms of hydroquinone on bladder cancer using network toxicology, Mendelian randomization analysis, molecular docking, and molecular dynamics simulations.
   Discov Oncol. 2026 Feb 27. doi: 10.1007/s12672-025-04114.
   PubMed    
   
   
   

6. BENIJTS R, Akand M, Tipirdamaz M, Mennes J, et al
   External validation and comparison of nomograms for prediction of long-term disease recurrence and survival for bladder cancer patients who undergo radical cystectomy.
   Minerva Urol Nephrol. 2026 Feb 27. doi: 10.23736/S2724-6051.25.06600.
   PubMed    
   Abstract available
   
   

7. YING X, Huang Y, Huang J, Cai Q, et al
   m(5)C-Modified tRF3b-Cys(GCA)-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4.
   Adv Sci (Weinh). 2026 Feb 27:e22294. doi: 10.1002/advs.202522294.
   PubMed    
   Abstract available
   
   

8. MATSUO T, Mori S, Honda H, Kakita S, et al
   Preoperative Gamma-Glutamyltransferase-to-Lymphocyte Ratio as an Independent Prognostic Biomarker in Patients Undergoing Radical Cystectomy for Bladder Cancer.
   Medicina (Kaunas). 2026;62:343.
   PubMed    
   Abstract available
   
   

9. PEREIRA M, Vale N
   Gene Expression-Guided Drug Repurposing in Oncology: Insights from Antiretroviral Agents in Prostate and Bladder Cancer.
   Genes (Basel). 2026;17:184.
   PubMed    
   Abstract available
   
   

10. SCHITCU VH, Munteanu VC, Borz MB, Cojocaru I, et al
    Genomic Subtypes and Computational Biomarkers in Non-Muscle-Invasive Bladder Cancer Guiding Optimal Timing of Radical Cystectomy and BCG Response Prediction.
    Genes (Basel). 2026;17:153.
    PubMed    
    Abstract available
    
    

11. CAN VG
    Molecular Characterization of Muscle-Invasive Bladder Cancer: Key MicroRNAs, Transcription Factors, and Differentially Expressed Genes.
    Genes (Basel). 2026;17:122.
    PubMed    
    Abstract available
    
    

12. OZYURT N, Turhan A
    Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.
    Diagnostics (Basel). 2026;16:574.
    PubMed    
    Abstract available
    
    

13. PARADA D, Onoiu AI, Iftimie S, Camps J, et al
    A Pilot Study Exploring Paraoxonase-1 Tissue Protein Expression and Circulating Levels in Bladder Cancer.
    Antioxidants (Basel). 2026;15:198.
    PubMed    
    Abstract available
    
    

14. BEKESCHUS S, Berner J, Edelmann J, Wolff CM, et al
    Synergistic Toxicity of Cold Gas Plasma and Cisplatin in Bladder Cancer Cells.
    Cancers (Basel). 2026;18:675.
    PubMed    
    Abstract available
    
    

15. GRIER AL, Zhong JY, Basourakos S, Calaway A, et al
    Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2026;18:623.
    PubMed    
    Abstract available
    
    

16. RIBEIRO E, Vale N
    Personalized Combination Therapy in Bladder Cancer: cAMP Modulators Synergize with 5-FU and Modulate Redox Programs.
    Cancers (Basel). 2026;18:562.
    PubMed    
    Abstract available
    
    

17. ZENG S, Xu Z, Xing S, Zhang Y, et al
    Exploratory study of olaparib combined with intravesical perfusion in the treatment of secondary bladder cancer after kidney transplantation: preliminary observations and discussion.
    Eur J Med Res. 2026 Feb 26. doi: 10.1186/s40001-026-04029.
    PubMed    
    Abstract available
    
    

18. BAEK SW, Byun YJ, Piao XM, Seo JW, et al
    Transcriptome-based high-frequency recurrence index predicts frequent recurrence in non-muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy.
    BMC Med. 2026 Feb 27. doi: 10.1186/s12916-026-04745.
    PubMed    
    Abstract available
    
    

19. HUANG GK, Zhang XX, Huang LY, Un HC, et al
    Tumor-infiltrating lymphocytes demonstrate potent anti-tumor efficacy and synergize with PD-1 blockade in bladder cancer.
    J Transl Med. 2026 Feb 26. doi: 10.1186/s12967-026-07924.
    PubMed    
    Abstract available
    
    

20. REN S, Dai R, Zheng Z, Liu Q, et al
    Corrigendum to "A novel bidirectional perfusion-like administered system for NIR-II fluorescence imaging precision diagnosis of bladder cancer" [Nanomed Nanotechnol Biol Med 49 (April 2023) 102661].
    Nanomedicine. 2026 Feb 25:102916. doi: 10.1016/j.nano.2026.102916.
    PubMed    
    
    
    

21. SCHMID SC, Jahnen M, Schiller K, Sauter A, et al
    Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).
    Eur Urol Oncol. 2026 Feb 25:S2588-9311(26)00056.
    PubMed    
    Abstract available
    
    

22. TRAN MA, Cho BA, Izadmehr S, Yoo SK, et al
    A tumor-promoting inflammatory SPP1+ macrophage-IL-6-CRP axis drives immune dysfunction in bladder cancer.
    Cancer Discov. 2026 Feb 27. doi: 10.1158/2159-8290.CD-25-1774.
    PubMed    
    Abstract available
    
    

23. KATONGTUNG P, Shiangjen K, Cholamjiak W, Naravejsakul K, et al
    MRI-Based Bladder Cancer Staging via YOLOv11 Segmentation and Deep Learning Classification.
    Diseases. 2026;14:45.
    PubMed    
    Abstract available
    
    

24. PAVALEAN MI, Lambrescu IM, Gaina G, Madan VL, et al
    CD36 rs1761667 Polymorphism and Its Impact on Molecular Signatures in Bladder Cancer.
    Diseases. 2026;14:44.
    PubMed    
    Abstract available
    
    

25. BUONERBA C, Baio R, Crocetto F, Bruzzese D, et al
    BLOSSOM Dietary Habits and 1-Year Intravesical Recurrence in High-Risk Non-Muscle-Invasive Bladder Cancer Treated with BCG.
    Curr Oncol. 2026;33:128.
    PubMed    
    Abstract available
    
    

26. ZHANG X, Su S, Liu L, Song F, et al
    Preoperative gamma-glutamyl transferase to lymphocyte ratio predicts recurrence in non-muscle-invasive bladder cancer.
    Front Oncol. 2026;16:1724968.
    PubMed    
    Abstract available
    
    

27. NIU S, Li L, Jia W, Feng H, et al
    Quantitative proteomic analysis reveals different characteristics of bladder cancer cells after exposure to bisphenol A.
    FEBS Open Bio. 2026 Feb 25. doi: 10.1002/2211-5463.70221.
    PubMed    
    Abstract available
    
    

28. HABICHER M, Swoboda C, Hauptmann A, Koch C, et al
    Enhanced recovery after radical cystectomy for bladder cancer: a prospective observational case -control study.
    BMC Urol. 2026 Feb 25. doi: 10.1186/s12894-026-02093.
    PubMed    
    
    
    

29. LEE TJ, Qiu L, Long J, Mach KE, et al
    CystoDS: a multiclass endoscopy image dataset for artificial intelligence-assisted bladder cancer detection.
    Sci Data. 2026 Feb 26. doi: 10.1038/s41597-026-06887.
    PubMed    
    Abstract available
    
    

30. TAKEUCHI M, Tamada T
    Current Status and Future Perspective for Bladder Cancer MR Imaging and the Vesical Imaging-Reporting and Data System (VI-RADS) in Japan: Challenges and Solutions.
    Magn Reson Med Sci. 2026 Feb 26. doi: 10.2463/mrms.rev.2025-0213.
    PubMed    
    Abstract available
    
    

31. GUERRERO-RAMOS F
    BCG and Systemic Immunotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Lights and Shadows.
    Actas Urol Esp (Engl Ed). 2026 Feb 23:501936. doi: 10.1016/j.acuroe.2026.501936.
    PubMed    
    
    
    

32. WEI X, Cai L, Li N, Fang Y, et al
    High-throughput screening of bladder cancer exosome biomarkers by barcodes integrated herringbone microfluidics.
    Biosens Bioelectron. 2026;302:118545.
    PubMed    
    Abstract available
    
    

33. TRATNJEK L, Janev A, Kuret T, Jerman UD, et al
    The interplay of dietary sugar, chronic inflammation, and bladder cancer: mechanistic insights, evidence, and prevention strategies.
    Front Immunol. 2026;17:1731784.
    PubMed    
    Abstract available
    
    

34. WANG Y, Wu N, Zhang S
    Ferroptosis-autophagy crosstalk in bladder cancer: mechanisms and therapeutic implications.
    Mol Cancer. 2026 Feb 24. doi: 10.1186/s12943-026-02608.
    PubMed    
    
    
    

35. ADIB E, Nassar AH, Alaiwi SA, Baca SC, et al
    Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular Subtypes.
    Mol Cancer Res. 2026 Feb 24. doi: 10.1158/1541-7786.MCR-25-1385.
    PubMed    
    Abstract available
    
    

36. GOEL V, Jain A, Basu D, Patnaik N, et al
    Comparative Efficacy and Toxicity of Gemcitabine-Cisplatin vs. Gemcitabine-Carboplatin in Metastatic Carcinoma of the Urinary Bladder: A Retrospective Review.
    Gulf J Oncolog. 2025;1:60-66.
    PubMed    
    Abstract available
    
    

37. SHAN M, Wang X, Wang Z, Xu C, et al
    NIR-II aggregation-induced emission sonosensitizer for pyroptosis induction in bladder cancer.
    Bioact Mater. 2026;61:229-242.
    PubMed    
    Abstract available
    
    

38. HONG X, Wang G, Hong T, Liu X, et al
    Glycolysis-related genes for bladder cancer: A Mendelian randomization analysis.
    Biochem Biophys Rep. 2026;45:102501.
    PubMed    
    Abstract available
    
    

39. PEYROTTES A, Masson-Lecomte A, Aregui A, Meria P, et al
    [Specificities of oncologic surgery in elder patients].
    Rev Prat. 2026;76:60-65.
    PubMed    
    Abstract available
    
    

40. ZHANG L, Zhong Y, Yang G, Huang L, et al
    Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions.
    Front Digit Health. 2026;8:1708289.
    PubMed    
    Abstract available
    
    

41. ZHANG L, Gong Y, Chen J, Li M, et al
    Prognostic significance of calcium signaling-related genes in bladder cancer and the role of ATP2B4 in regulating mitochondrial calcium ion levels via the VDAC1/MCU pathway.
    Front Immunol. 2026;17:1561666.
    PubMed    
    Abstract available
    
    

42. KUCAN BRLIC P, Bellulovich E, Golemac M, Jaksic A, et al
    High PVR protein expression marks clear cell renal cell carcinoma with metastatic spread.
    Front Immunol. 2026;17:1754848.
    PubMed    
    Abstract available
    
    

43. MUNERA-MARAVILLA E, Perez-Escavy M, Rubio C, Segovia C, et al
    Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models.
    J Exp Clin Cancer Res. 2026 Feb 23. doi: 10.1186/s13046-026-03677.
    PubMed    
    
    
    

44. CUI J, Chen S, Liu X, Jiang X, et al
    PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6.
    Cell Death Dis. 2026 Feb 23. doi: 10.1038/s41419-026-08498.
    PubMed    
    Abstract available
    
    

45. SEO J, Park JM, Park DJ, Seo I, et al
    Exploration of the Tumor Transcriptomic and Immune Landscape Following Repeated Transurethral Resection in Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2026 Jan 23:102513. doi: 10.1016/j.clgc.2026.102513.
    PubMed    
    Abstract available
    
    

46. XU L, Lin Y, Shi G, Zhang L, et al
    Single-Cell Insights into Cisplatin Resistance Mechanisms in Bladder Cancer Tumor Microenvironment.
    J Biol Chem. 2026 Feb 20:111304. doi: 10.1016/j.jbc.2026.111304.
    PubMed    
    Abstract available
    
    

47. MISURKA J, Berjaoui MB, Lajkosz K, Cockburn J, et al
    PA- versus urologist-performed flexible cystoscopy: A comparative study.
    JAAPA. 2026;39:34-36.
    PubMed    
    Abstract available
    
    

48. LUO C, Kuang X, Dai Y, Cai Z, et al
    DNA methylation-mediated silencing of HNF1B promotes bladder cancer progression.
    Clin Epigenetics. 2026 Feb 21. doi: 10.1186/s13148-026-02079.
    PubMed    
    Abstract available
    
    

49. XU DM, Chen J, Lin SB, Xu TY, et al
    ATIC facilitates the malignant progression of bladder cancer by modulating AMPK-mTOR-S6K1 axis under folate reprogramming.
    J Transl Med. 2026 Feb 21. doi: 10.1186/s12967-026-07830.
    PubMed    
    
    
    

50. CHEN Q, Wu K, Cai B, Yu X, et al
    LncRNA miR17HG promotes tumor progression through AXIN2 by sponging miR-144-3p in bladder cancer.
    World J Surg Oncol. 2026 Feb 21. doi: 10.1186/s12957-026-04246.
    PubMed    
    
    
    

51. FALQUET M, El Ahanidi H, Gomez-Cadena A, Su Z, et al
    Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.
    Nat Commun. 2026 Feb 21. doi: 10.1038/s41467-026-69841.
    PubMed    
    Abstract available
    
    

52. STEMPEL MH, Quezada JP, Belz B, Sun F, et al
    Implications of hemoglobin, albumin, lymphocyte, platelet (HALP) score as a predictor of neoadjuvant chemotherapy response in bladder cancer patients.
    Urol Oncol. 2026 Feb 20:111005. doi: 10.1016/j.urolonc.2026.111005.
    PubMed    
    Abstract available
    
    

53. DI LORENZO G, Di Maio M, Buonerba C
    Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.
    Oncol Ther. 2026 Feb 21. doi: 10.1007/s40487-026-00417.
    PubMed    
    Abstract available
    
    

54. CHEN C, Yang Y, Niu H, Tang Y, et al
    Interfacial Electric Locking of the Aptamer Conformation for Accurate Liquid Biopsy Detection.
    Nano Lett. 2026;26:2371-2380.
    PubMed    
    Abstract available
    
    

55. SAKTHIVEL DK, Prabhakar P, Iyub MJR, Garje R, et al
    Comparative Analysis of Signet Ring and Non-Signet Ring Urachal Adenocarcinomas: A National Cancer Database Study.
    Clin Genitourin Cancer. 2026;24:102495.
    PubMed    
    Abstract available
    
    

56. TAWAGI K, Khaki AR, Chablani PV, Hoffman-Censits J, et al
    Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.
    Clin Genitourin Cancer. 2026;24:102487.
    PubMed    
    Abstract available
    
    

57. SAHIN KC, Simsekoglu MF, Ozden SB, Ercili B, et al
    Histologic subtypes and divergent differentiations of urothelial carcinoma: Prognostic implications and clinical insights.
    Surg Oncol. 2026;64:102344.
    PubMed    
    Abstract available
    
    

58. HUNDEBOLL JH, Olesen AF, Wessel I, Magkos F, et al
    Not just about weight: Identifying hidden nutritional vulnerability after radical cystectomy.
    Eur J Clin Nutr. 2025 Dec 10. doi: 10.1038/s41430-025-01694.
    PubMed    
    Abstract available
    
    

59. PAN W, Xing J, Chen X, Xue R, et al
    Urinary biomarkers in cancer detection: explorations, advancements, challenges, and future directions.
    Int J Surg. 2026;112:4762-4788.
    PubMed    
    Abstract available
    
    

60. WENG HW, Ting HK, Wang HH, Peng TJ, et al
    Targeting neuropilin-1 and neutralizing interleukin-6 inhibits cancer stem cell formation in bladder cancer cells.
    J Transl Med. 2026 Mar 4. doi: 10.1186/s12967-026-07943.
    PubMed    
    
    
    

61. ROUPRET M
    Reply to Letter to the Editor: 'ALBAN (GETUG-AFU 37): a phase 3, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guerin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle invasive bladd
    Ann Oncol. 2026 Mar 3:S0923-7534(26)00046-3. doi: 10.1016/j.annonc.2026.
    PubMed    
    
    
    

62. ZHOU M, Xue X, Li H, Chen Z, et al
    Decoding the metabolic-immune axis for novel therapeutics in bladder cancer.
    Biochim Biophys Acta Rev Cancer. 2026 Mar 2:189569.
    PubMed    
    Abstract available
    
    

63. YANG M, Chai X, Ye D, Zhao A, et al
    Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guerin immunotherapy.
    J Med Econ. 2026;29:672-687.
    PubMed    
    Abstract available
    
    

64. BANG S, Joo SM, Kim DK, Kwon JK, et al
    Preoperative selective arterial embolization followed by transurethral resection of bladder tumor for large bladder tumors: Early clinical experiences.
    Investig Clin Urol. 2026;67:162-169.
    PubMed    
    Abstract available
    
    

65. YANG Q, Zhou D, Beasley A, Liu Y, et al
    Identification of SLC3A2 as a Potential Therapeutic Target of Ferroptosis in Bladder Cancer.
    Arch Esp Urol. 2026;79:36-48.
    PubMed    
    Abstract available
    
    

66. MCKAY RR, Tipirneni A, Bangs R, Guercio BJ, et al
    Neoadjuvant Systemic Therapy in Kidney and Bladder Cancer: Current Evidence and Emerging Paradigms.
    Am Soc Clin Oncol Educ Book. 2026;46:e516902.
    PubMed    
    Abstract available
    
    

67. GIRGIN R, Mungan NA
    Turkish urologists' knowledge and attitudes on lifestyle advice for bladder cancer: a national survey.
    Support Care Cancer. 2026;34:260.
    PubMed    
    Abstract available
    
    

68. YAMADA S, Sato M, Osawa T, Harabayashi T, et al
    Longitudinal Impact of Urinary Diversion on Health-Related Quality of Life After Radical Cystectomy: A Multicenter Study in Japan.
    Cancer Sci. 2026;117:739-748.
    PubMed    
    Abstract available
    
    

69. NOGUEIRA CM, Machado C, Santos RB, Faustino AS, et al
    Infiltrated penile papules as a cutaneous manifestation of disseminated BCGitis: A rare dermatologic presentation.
    Int J STD AIDS. 2026;37:444-446.
    PubMed    
    Abstract available
    
    

70. STARRETT JH, Allen EL, Neal M, Iyer S, et al
    Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.
    Mol Cancer Ther. 2026;25:408-415.
    PubMed    
    Abstract available
    
    

71. HUMAYUN-ZAKARIA N, Tura BJ, van Hemelrijck M, Bryan RT, et al
    Aligning bladder cancer research with patient needs: an update on research priorities.
    BJU Int. 2026 Feb 27. doi: 10.1111/bju.70206.
    PubMed    
    
    
    

72. SCILIPOTI P, Zaurito P, Longoni M, Tremolada G, et al
    Impact of BCG failure patterns on efficacy of intravesical gemcitabine/docetaxel in high-risk non-muscle-invasive bladder cancer.
    BJU Int. 2026 Feb 25. doi: 10.1111/bju.70182.
    PubMed    
    Abstract available
    
    

73. BARRETTA A, Piazza P, Catanzaro C, Mottaran A, et al
    Is there still a role for ureteric frozen section analysis during radical cystectomy?
    BJU Int. 2026;137:659-666.
    PubMed    
    Abstract available
    
    

74. CLARK PE
    Re: Durvalumab in combination with BCG for BCG-naive, high risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
    Eur Urol. 2026 Feb 25:S0302-2838(26)01995-0. doi: 10.1016/j.eururo.2026.
    PubMed    
    
    
    

75. NUSBAUM DJ, Li R, Peyton CC, Spiess PE, et al
    Less Is More? How Much Bacillus Calmette-Guerin (BCG) Is Enough for BCG-naive High-risk Non-muscle invasive Bladder Cancer?
    Eur Urol. 2026 Feb 24:S0302-2838(26)02001-4. doi: 10.1016/j.eururo.2026.
    PubMed    
    
    
    

76. LIU P, Chen J, Zhou J
    Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2026 Feb 24:S0302-2838(26)01997-4. doi: 10.1016/j.eururo.2026.
    PubMed    
    
    
    

77. GUPTA S, Li R, Hensley PJ, Daneshmand S, et al
    Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.
    Eur Urol. 2026 Feb 21:S0302-2838(26)00059-X. doi: 10.1016/j.eururo.2026.
    PubMed    
    Abstract available
    
    

78. SANO T, Ohe C, Motoki Y, Nakamoto T, et al
    Prognostic Significance of Tertiary Lymphoid Structure-Like Lymphocyte Aggregates in Routine Histopathological Examination in Bladder Cancer.
    Int J Urol. 2026;33:e70392.
    PubMed    
    Abstract available
    
    

79. PELLEGRINO P, Scherer TP, Wettstein MS, Baumgartner M, et al
    Development of a nomogram for prediction of postoperative bleeding after transurethral resection of bladder tumors.
    Int Urol Nephrol. 2026;58:921-929.
    PubMed    
    Abstract available
    
    

80. NISHIMURA F, Oniki K, Yamashita A, Honda K, et al
    Prognostic role of intramuscular adipose tissue content in patients with urothelial carcinoma treated with pembrolizumab.
    Int Urol Nephrol. 2026;58:861-871.
    PubMed    
    Abstract available
    
    

81. ZHANG L, Cao J, Gao Z, Han C, et al
    Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.
    BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15806.
    PubMed